JPRN-UMIN000015696已完成未知
Safety and efficacy of tyrosine kinase inhibitors for the treatment of severe and progressive pulmonary hypertension - Safety and efficacy of TKI for severe progressive PH
Hokkaido University Hospital, Internal medicine I0 个研究点目标入组 5 人开始时间: 2014年11月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Those to whom imatinib and sorafenib are contraindicated 2. Those to whom the principle investigator deemed to be unsuitable for enrollment
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate activity and safety of third line of treatment after two previous therapies in patients with renal cell carcinomaMetastatic renal cells carcinomaMedDRA version: 11.0Level: HLTClassification code 10038408Term: Renal cell carcinomasSystem Organ Class: 100000004864EUCTR2014-001956-52-ITFondazione IRCCS Istituto Nazionale dei Tumori44
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195
进行中（未招募）
2 期
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World PopulationChronic Myeloid LeukemiaChronic Myeloid Leukemia, BCR/ABL-Positive, in RemissionChronic Myeloid Leukemia in RemissionNCT04626024Baylor College of Medicine17
尚未招募
3 期
Efficacy of Rho-Kinase inhibitor in Post-operative Striate KeratopathyCTRI/2024/04/065348BLDE UNIVERSITY
进行中（未招募）
1 期
Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical TrialsPatients who have been treated in previous AG-013736 oncology studiesEUCTR2005-000051-15-DEPfizer Pharma GmbH50